The influence of nucleoside transporter on pharmacokinetics, effect and adverse events of ribaviri
Not Applicable
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000004309
- Lead Sponsor
- Tsukuba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) Anemia 2) Virus infection last 4 weeks prior to the study 3) Medication last 2 weeks prior to the study 4) Participation in a clinical trial last 3 months prior to the study 5) Intake of alcohol last 48 hours prior to the study 6) Blood donation more than 400 mL last 6 months prior to the study 7) Possible the autoimmune disease 8) Allergic reaction 9) Alcohol or drug abuse 10) Positive for HBs antigen, HCV antibody, and syphilis 11) Other inappropriate cases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetics of ribavirin
- Secondary Outcome Measures
Name Time Method